- Conditions
- Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
- Interventions
- Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 62
- States / cities
- Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide, Elotuzumab, Dexamethasone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Milwaukee, Wisconsin